NICE guidelines (NG28) support the use of GLP-1 receptor agonists for type 2 diabetes when glycaemic targets are not achieved with other therapies, and for weight management in specific circumstances (TA875 for Wegovy, TA664 for Saxenda)
Someone who has completed a GLP-1 consult and their first month of the GLP-1 Program
For some, this less frequent dosing makes the injection route more convenient
Stopping points If side effects do not resolve with slower injection or dose reduction, the most common research-planning response is to pause, reassess, and consult a clinician before resuming
Shake the bottle for 20-30 seconds
Urinary Tract Abnormalities : Structural issues, like kidney stones or birth defects in the urinary system, can obstruct urine flow and make infections more likely